For example, the combination of axitinib, a VEGF inhibitor, and crizotinib, a c‐Met inhibitor, has demonstrated significant improvements in the therapeutic efficacy of RCC by simultaneously targeting these two key pathways.92 The gene discussed is MET; the disease is renal cell carcinoma.